{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:48:28Z","timestamp":1793296108269,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12519-022-00612-7","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T11:04:03Z","timestamp":1663758243000},"page":"107-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of hepatitis C in children and adolescents: how far have we reached?"],"prefix":"10.1007","volume":"19","author":[{"given":"Vybhav","family":"Venkatesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthivasan","family":"Seetharaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3320-8823","authenticated-orcid":false,"given":"Neha","family":"Anushree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"612_CR1","unstructured":"World Health Organization. Hepatitis C. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 14 Mar 2022."},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S2468-1253(19)30385-1","volume":"5","author":"J Schmelzer","year":"2020","unstructured":"Schmelzer J, Dugan E, Blach S, Coleman S, Cai Z, DePaola M, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5:374\u201392.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"612_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/MPG.0000000000002814","volume":"71","author":"DH Leung","year":"2020","unstructured":"Leung DH, Squires JE, Jhaveri R, Kerkar N, Lin CH, Mohan P, et al. Hepatitis C in 2020: a North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper. J Pediatr Gastroenterol Nutr. 2020;71:407\u201317.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/MPG.0000000000001872","volume":"66","author":"G Indolfi","year":"2018","unstructured":"Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:505\u201315.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S2468-1253(19)30046-9","volume":"4","author":"G Indolfi","year":"2019","unstructured":"Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477\u201387.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"612_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100227","volume":"3","author":"F Malik","year":"2021","unstructured":"Malik F, Bailey H, Chan P, Collins IJ, Mozalevskis A, Thorne C, et al. Where are the children in national hepatitis C policies? a global review of national strategic plans and guidelines. JHEP Rep. 2021;3:100227.","journal-title":"JHEP Rep."},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1086\/315264","volume":"181","author":"PA Tovo","year":"2000","unstructured":"Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis. 2000;181:419\u201324.","journal-title":"J Infect Dis"},{"key":"612_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/jmv.10405","volume":"70","author":"M Resti","year":"2003","unstructured":"Resti M, Jara P, Hierro L, Azzari C, Giacchino R, Zuin G, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol. 2003;70:373\u20137.","journal-title":"J Med Virol"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1086\/430601","volume":"41","author":"European Paediatric Hepatitis C Virus Network","year":"2005","unstructured":"European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41:45\u201351.","journal-title":"Clin Infect Dis"},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1053\/j.gastro.2008.02.082","volume":"134","author":"F Bortolotti","year":"2008","unstructured":"Bortolotti F, Verucchi G, Camm\u00e0 C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008;134:1900\u20137.","journal-title":"Gastroenterology"},{"key":"612_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1086\/345908","volume":"36","author":"P Jara","year":"2003","unstructured":"Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003;36:275\u201380.","journal-title":"Clin Infect Dis"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1440-1746.2004.03463.x","volume":"19","author":"S Rerksuppaphol","year":"2004","unstructured":"Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol. 2004;19:1357\u201362.","journal-title":"J Gastroenterol Hepatol"},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1086\/497141","volume":"41","author":"R Iorio","year":"2005","unstructured":"Iorio R, Giannattasio A, Sepe A, Terracciano LM, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005;41:1431\u20137.","journal-title":"Clin Infect Dis"},{"key":"612_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/01.mpg.0000228117.52229.32","volume":"43","author":"C Rumbo","year":"2006","unstructured":"Rumbo C, Fawaz RL, Emre SH, Suchy FJ, Kerkar N, Morotti RA, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr. 2006;43:209\u201316.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"174.e1","DOI":"10.1016\/j.jpeds.2006.11.037","volume":"150","author":"P Mohan","year":"2007","unstructured":"Mohan P, Colvin C, Glymph C, Chandra RR, Kleiner DE, Patel KM, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr. 2007;150:174.e1.","journal-title":"J Pediatr"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1365-2893.2009.01135.x","volume":"16","author":"ST Chen","year":"2009","unstructured":"Chen ST, Ni YH, Chen PJ, Chen HL, Jeng YM, Lu MY, et al. Low viraemia at enrollment in children with chronic hepatitis C favours spontaneous viral clearance. J Viral Hepat. 2009;16:796\u2013801.","journal-title":"J Viral Hepat"},{"key":"612_CR17","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1111\/j.1365-2893.2011.01456.x","volume":"18","author":"M Abdel-Hady","year":"2011","unstructured":"Abdel-Hady M, Bunn SK, Sira J, Brown RM, Brundler MA, Davies P, et al. Chronic hepatitis C in children-review of natural history at a national centre. J Viral Hepat. 2011;18:e535\u201340.","journal-title":"J Viral Hepat"},{"key":"612_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00431-014-2286-6","volume":"173","author":"S Garazzino","year":"2014","unstructured":"Garazzino S, Calitri C, Versace A, Alfarano A, Scolfaro C, Bertaina C, et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr. 2014;173:1025\u201331.","journal-title":"Eur J Pediatr"},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/hep.20030","volume":"39","author":"MA Casiraghi","year":"2004","unstructured":"Casiraghi MA, De Paschale M, Roman\u00f2 L, Biffi R, Assi A, Binelli G, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004;39:90\u20136.","journal-title":"Hepatology"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00535-017-1351-0","volume":"53","author":"T Mizuochi","year":"2018","unstructured":"Mizuochi T, Takano T, Yanagi T, Ushijima K, Suzuki M, Miyoshi Y, et al. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J Gastroenterol. 2018;53:419\u201326.","journal-title":"J Gastroenterol"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2018.11.013","volume":"70","author":"L Modin","year":"2019","unstructured":"Modin L, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving WL, et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol. 2019;70:371\u20138.","journal-title":"J Hepatol"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/MPG.0000000000000275","volume":"58","author":"G Indolfi","year":"2014","unstructured":"Indolfi G, Mangone G, Calvo PL, Bartolini E, Regoli M, Serranti D, et al. Interleukin 28B rs12979860 single-nucleotide polymorphism predicts spontaneous clearance of hepatitis C virus in children. J Pediatr Gastroenterol Nutr. 2014;58:666\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/apt.13430","volume":"43","author":"G Indolfi","year":"2016","unstructured":"Indolfi G, Mangone G, Moriondo M, Serranti D, Bartolini E, Azzari C, et al. Altered natural killer cells subsets distribution in children with hepatitis C following vertical transmission. Aliment Pharmacol Ther. 2016;43:125\u201333.","journal-title":"Aliment Pharmacol Ther"},{"key":"612_CR24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/hep.22094","volume":"47","author":"ZD Goodman","year":"2008","unstructured":"Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology. 2008;47:836\u201343.","journal-title":"Hepatology"},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"S654","DOI":"10.1093\/ofid\/ofy210.1868","volume":"5","author":"J Honegger","year":"2018","unstructured":"Honegger J, Crim L, Gowda C, Sanchez PJ. Polymerase chain reaction (PCR) for detection of vertically acquired hepatitis C virus (HCV) infection in early infancy. Open Forum Infect Dis. 2018;5:S654.","journal-title":"Open Forum Infect Dis"},{"key":"612_CR26","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531733\/. Accessed 27 Apr 2022."},{"key":"612_CR27","unstructured":"Infectious Disease Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org\/unique-populations\/children. Accessed 27Apr 2022."},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2265.2007.03009.x","volume":"68","author":"G Indolfi","year":"2008","unstructured":"Indolfi G, Stagi S, Bartolini E, Salti R, de Martino M, Azzari C, et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol. 2008;68:117\u201321.","journal-title":"Clin Endocrinol"},{"key":"612_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00467-008-0948-1","volume":"24","author":"T Sugiura","year":"2009","unstructured":"Sugiura T, Yamada T, Kimpara Y, Fujita N, Goto K, Koyama N. Effects of pegylated interferon \u03b1-2a on hepatitis-C-virus-associated glomerulonephritis. Pediatr Nephrol. 2009;24:199\u2013202.","journal-title":"Pediatr Nephrol"},{"key":"612_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1572-0241.2003.07293.x","volume":"98","author":"M Guido","year":"2003","unstructured":"Guido M, Bortolotti F, Leandro G, Jara P, Hierro L, Larrauri J, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol. 2003;98:660\u20133.","journal-title":"Am J Gastroenterol"},{"key":"612_CR31","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1440-1746.2007.04936.x","volume":"22","author":"A Nydegger","year":"2007","unstructured":"Nydegger A, Heine RG, Ranuh R, Gegati-Levy R, Crameri J, Oliver MR. Changing incidence of acute pancreatitis: 10-year experience at the Royal Children\u2019s Hospital, Melbourne. J Gastroenterol Hepatol. 2007;22:1313\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"612_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/MPG.0b013e318185998f","volume":"48","author":"JR Rodrigue","year":"2009","unstructured":"Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 2009;48:341\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/1359104520974434","volume":"26","author":"IM Ibrahim","year":"2021","unstructured":"Ibrahim IM, Haikal A, Ali KM, AlSayed MAL, Barakat TE. Cognitive impairment in children with chronic Hepatitis C Virus: case control study. Clin Child Psychol Psychiatry. 2021;26:381\u201392.","journal-title":"Clin Child Psychol Psychiatry"},{"key":"612_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jpeds.2020.08.088","volume":"230","author":"E Greenaway","year":"2021","unstructured":"Greenaway E, Haines A, Ling SC, Krahn M. Treatment of chronic hepatitis C in young children reduces adverse outcomes and is cost-effective compared with deferring treatment to adulthood. J Pediatr. 2021;230:38-45.e2.","journal-title":"J Pediatr"},{"key":"612_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jpeds.2018.12.012","volume":"207","author":"J Nguyen","year":"2019","unstructured":"Nguyen J, Barritt AS, Jhaveri R. Cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with hepatitis C virus infection. J Pediatr. 2019;207:90\u20136.","journal-title":"J Pediatr"},{"key":"612_CR36","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"JM Pawlotsky","year":"2020","unstructured":"Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol"},{"key":"612_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","volume":"10","author":"M Omata","year":"2016","unstructured":"Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702\u201326.","journal-title":"Hepatol Int"},{"key":"612_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1515\/jtim-2017-0007","volume":"5","author":"A Geddawy","year":"2017","unstructured":"Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. J Transl Int Med. 2017;5:8\u201317.","journal-title":"J Transl Int Med."},{"key":"612_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/hep.28995","volume":"66","author":"WF Balistreri","year":"2017","unstructured":"Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, et al. The safety and effectiveness of ledipasvir\u2212sofosbuvir in adolescents 12\u201317 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66:371\u20138.","journal-title":"Hepatology"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/apt.14502","volume":"47","author":"HR El-Khayat","year":"2018","unstructured":"El-Khayat HR, Kamal EM, El-Sayed MH, El-Shabrawi M, Ayoub H, RizK A, et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther. 2018;47:838\u201344.","journal-title":"Aliment Pharmacol Ther"},{"key":"612_CR41","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MPG.0000000000002101","volume":"67","author":"H El-Karaksy","year":"2018","unstructured":"El-Karaksy H, Mogahed EA, Abdullatif H, Ghobrial C, El-Raziky MS, El-Koofy N, et al. Sustained viral response in genotype 4 chronic hepatitis C virus\u2013infected children and adolescents treated with sofosbuvir\/ledipasvir. J Pediatr Gastroenterol Nutr. 2018;67:626\u201330.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/MPG.0000000000002139","volume":"68","author":"RK Dhiman","year":"2019","unstructured":"Dhiman RK, Grover GS, Premkumar M, Taneja S, Duseja A, Rathi S, et al. Direct-acting antiviral therapy is safe and effective in pediatric chronic hepatitis C: the public health perspective. J Pediatr Gastroenterol Nutr. 2019;68:74\u201380.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR43","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.3390\/jcm10184176","volume":"10","author":"M Pokorska-\u015apiewak","year":"2021","unstructured":"Pokorska-\u015apiewak M, Dobrzeniecka A, Aniszewska M, Marczy\u0144ska M. Real-Life experience with ledipasvir\/sofosbuvir for the treatment of chronic hepatitis C virus infection with genotypes 1 and 4 in children aged 12 to 17 years\u2014results of the POLAC Project. J Clin Med. 2021;10:4176.","journal-title":"J Clin Med"},{"key":"612_CR44","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MPG.0000000000003406","volume":"74","author":"MH El-Sayed","year":"2022","unstructured":"El-Sayed MH, Ebeid FSE, Zekri AR, Massetto B, Kersey K, Zhang F, et al. Ledipasvir-sofosbuvir in adolescents with chronic hepatitis C and hematological malignancies undergoing chemotherapy. J Pediatr Gastroenterol Nutr. 2022;74:626\u201330.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR45","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/hep.30123","volume":"68","author":"KF Murray","year":"2018","unstructured":"Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6\u201311. Hepatology. 2018;68:2158\u201366.","journal-title":"Hepatology"},{"key":"612_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.30830","volume":"71","author":"KB Schwarz","year":"2020","unstructured":"Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C. Hepatology. 2020;71:422\u201330.","journal-title":"Hepatology"},{"key":"612_CR47","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/apt.14677","volume":"47","author":"MHF El-Shabrawi","year":"2018","unstructured":"El-Shabrawi MHF, Kamal NM, El-Khayat HR, Kamal EM, AbdElgawad MMAH, Yakoot M. A pilot single arm observational study of sofosbuvir\/ledipasvir (200 + 45 mg) in 6- to 12- year old children. Aliment Pharmacol Ther. 2018;47:1699\u2013704.","journal-title":"Aliment Pharmacol Ther"},{"key":"612_CR48","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/hep.29278","volume":"66","author":"S Wirth","year":"2017","unstructured":"Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, et al. Sofosbuvir and ribavirin in adolescents 12\u201317 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102\u201310.","journal-title":"Hepatology"},{"key":"612_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hep.30821","volume":"71","author":"P Rosenthal","year":"2020","unstructured":"Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, Lin C, Kelly DA, Nightingale S, et al. Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2020;71:31\u201343.","journal-title":"Hepatology"},{"key":"612_CR50","first-page":"423","volume":"27","author":"MA Hashmi","year":"2017","unstructured":"Hashmi MA, Cheema HA. Effectiveness and safety of sofosbuvir in treatment-n\u00e4ive children with hepatitis C infection. J Coll Physicians Surg Pak. 2017;27:423\u20136.","journal-title":"J Coll Physicians Surg Pak"},{"key":"612_CR51","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep.30840","volume":"71","author":"MM Jonas","year":"2020","unstructured":"Jonas MM, Squires RH, Rhee SM, Lin C, Bessho K, Feiterna-Sperling C, et al. Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology. 2020;71:456\u201362.","journal-title":"Hepatology"},{"key":"612_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31841","volume":"74","author":"MM Jonas","year":"2021","unstructured":"Jonas MM, Rhee S, Kelly DA, Del Valle-Segarra A, Feiterna-Sperling C, Gilmour S, et al. Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in children with chronic HCV: part 2 of the DORA study. Hepatology. 2021;74:19\u201327.","journal-title":"Hepatology"},{"key":"612_CR53","first-page":"570A","volume":"72","author":"EM Sokal","year":"2020","unstructured":"Sokal EM, Schwarz KB, Rosenthal P, Verucchi G, Lin CH, Balistreri WF, et al. Safety and efficacy of sofosbuvir\/velpatasvir for the treatment of chronic hepatitis C infection in children and adolescents aged 3 to 17 years old through 24 weeks posttreatment. Hepatology. 2020;72:570A.","journal-title":"Hepatology"},{"key":"612_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13490","volume":"23","author":"SR Jaiswal","year":"2021","unstructured":"Jaiswal SR, Bhakuni P, Soni M, Gupta M, Thatai A, Chakrabarti S. Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation. Transpl Infect Dis. 2021;23:e13490.","journal-title":"Transpl Infect Dis"},{"key":"612_CR55","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1016\/S0168-8278(17)30642-6","volume":"66","author":"M El-Sayed","year":"2017","unstructured":"El-Sayed M, Hassany M, Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in egyptian adolescents with chronic hepatitis C virus Infection. J Hepatol. 2017;66:S178.","journal-title":"J Hepatol."},{"key":"612_CR56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MPG.0000000000001968","volume":"67","author":"M Yakoot","year":"2018","unstructured":"Yakoot M, El-Shabrawi MH, AbdElgawad MM, Mahfouz AA, Helmy S, Abdo AM, et al. Dual sofosbuvir\/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;67:86\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR57","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPG.0000000000001838","volume":"66","author":"MH El-Shabrawi","year":"2018","unstructured":"El-Shabrawi MH, Abdo AM, El-Khayat HR, Yakoot M. Shortened 8 weeks course of dual sofosbuvir\/daclatasvir therapy in adolescent patients, with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;66:425\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"612_CR58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/jvh.13032","volume":"26","author":"TY Abdel Ghaffar","year":"2019","unstructured":"Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, et al. Safety and efficacy of combined sofosbuvir\/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4. J Viral Hepat. 2019;26:263\u201370.","journal-title":"J Viral Hepat"},{"key":"612_CR59","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/INF.0000000000003282","volume":"40","author":"TR Cressey","year":"2021","unstructured":"Cressey TR, Abbassi M, Lallemant M, Indolfi G, Al-Nahari M, Farid S, et al. Effective and safe daclatasvir drug exposures predicted in children using adult formulations. Pediatr Infect Dis J. 2021;40:1081\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"612_CR60","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/hep4.1250","volume":"2","author":"DH Leung","year":"2018","unstructured":"Leung DH, Wirth S, Yao BB, Viani RM, Gonzalez-Peralta RP, Jonas MM, et al. Ombitasvir\/paritaprevir\/ritonavir with or without dasabuvir and with or without ribavirin for adolescents with HCV genotype 1 or 4. Hepatol Commun. 2018;2:1311\u20139.","journal-title":"Hepatol Commun"},{"key":"612_CR61","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1007\/s12325-020-01389-9","volume":"37","author":"P Rosenthal","year":"2020","unstructured":"Rosenthal P, Narkewicz MR, Yao BB, Jolley CD, Lobritto SJ, Wen J, et al. Ombitasvir, paritaprevir, ritonavir, and dasabuvir mini-tabs plus ribavirin for children aged 3\u201311 years with hepatitis C genotype 1a. Adv Ther. 2020;37:3299\u2013310.","journal-title":"Adv Ther"},{"key":"612_CR62","first-page":"555A","volume":"72","author":"S Wirth","year":"2020","unstructured":"Wirth S, Gonzalez-Peralta RP, Squires RH, Mutschler F, Lang T, Pawlowska M, et al. Elbasvir\/grazoprevir in children aged 3 to <18 years with chronic hepatitis c virus (HCV) genotype (GT) 1 or 4 infection: final results from an iterative pharmacokinetic (pk) modeling study. Hepatology. 2020;72:555A.","journal-title":"Hepatology"},{"key":"612_CR63","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/hep.32393","volume":"76","author":"G Indolfi","year":"2022","unstructured":"Indolfi G, Kelly D, Nebbia G, Iorio R, Mania A, Giacomet V, et al. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection. Hepatology. 2022;76:445\u201355.","journal-title":"Hepatology."},{"key":"612_CR64","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1053\/j.gastro.2010.10.047","volume":"140","author":"KB Schwarz","year":"2011","unstructured":"Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology. 2011;140:450-8.e1.","journal-title":"Gastroenterology"},{"key":"612_CR65","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jhep.2010.01.016","volume":"52","author":"S Wirth","year":"2010","unstructured":"Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010;52:501\u20137.","journal-title":"J Hepatol"},{"key":"612_CR66","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MPG.0000000000001754","volume":"66","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Stepanova M, Balistreri W, Schwarz K, Murray KF, Rosenthal P, et al. Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Pediatr Gastroenterol Nutr. 2018;66:112\u20136.","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-022-00612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-022-00612-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-022-00612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T06:43:21Z","timestamp":1676616201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-022-00612-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s12519-022-00612-7","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"10 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}